Anaptysbio Stock News

Horizon (HZNP) files a supplemental biologics license application to the FDA for Krystexxa plus methotrexate to treat people living with uncontrolled gout.

Amgen (AMGN) signs a collaboration agreement with Generate Biomedicines to develop protein therapeutics across several therapeutic areas and multiple modalities.

SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that Hamza Suria, chief executive officer of AnaptysBio, will present an overview of AnaptysBio as part of the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 from 8:15 8:55 a.m. ET.

Related Stocks: ANAB ,

Invesco Ltd. boosted its stake in AnaptysBio, Inc. (NASDAQ:ANAB) by 7.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 20,083 shares of the biotechnology company’s stock after acquiring an additional 1,330 shares during the period. Invesco Ltd. owned 0.07% of […] The post AnaptysBio, Inc. (NASDAQ:ANAB) Shares Purchased by Invesco Ltd. appeared first on ETF Daily News .

AnaptysBio, Inc. (NASDAQ:ANAB) has earned a consensus recommendation of “Hold” from the seven brokerages that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the company. The average 1 year price target […]

Royal Bank of Canada lifted its stake in AnaptysBio, Inc. (NASDAQ:ANAB) by 3,944.6% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 37,777 shares of the biotechnology companys stock after buying an additional 36,843 shares during the period. Royal Bank of Canada owned []

SAN DIEGO, Nov. 29, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune

SAN DIEGO, Nov. 29, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced the appointment of Mr. Daniel Faga to the company’s Board of Directors.

Wall Street brokerages expect that AnaptysBio, Inc. (NASDAQ:ANAB) will report earnings per share (EPS) of $0.65 for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for AnaptysBios earnings. The lowest EPS estimate is ($1.01) and the highest is $6.71. AnaptysBio reported earnings per share of $1.20 during the same quarter last []

Wall Street analysts expect that AnaptysBio, Inc. (NASDAQ:ANAB) will announce $90.39 million in sales for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for AnaptysBios earnings, with estimates ranging from $1.90 million to $251.85 million. AnaptysBio reported sales of $60.00 million during the same quarter last year, which would suggest a positive []

Brokerages expect AnaptysBio, Inc. (NASDAQ:ANAB) to post $0.65 earnings per share for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for AnaptysBio’s earnings, with the lowest EPS estimate coming in at ($1.01) and the highest estimate coming in at $6.71. AnaptysBio reported earnings per share of $1.20 in the same quarter […]

SAN DIEGO, Nov. 15, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune

SAN DIEGO, Nov. 15, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that Hamza Suria, chief executive officer of AnaptysBio, will present an overview of AnaptysBio at the 2021 Jefferies London Healthcare Conference. The presentation will be available on Thursday, November 18, 2021, at 3:00 a.m. ET via https://wsw.com/webcast/jeff201/anab/1800252

SAN DIEGO, Nov. 15, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune co